Search
Black Diamond Therapeutics Inc
BDTXAdd to Watchlist
1.885USD
-0.015-0.79%
Market hours 09/24, 13:03（ET）
108.01MMarket Cap
LossP/E TTM
Black Diamond Therapeutics Inc (BDTX) Stock Price Target & Forecast
Analyst Rating
Based on 9 analysts giving stock ratings to Black Diamond Therapeutics Inc in the past month.
Buy
3 Strong Buy
5 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
10.000USD+405.05%
BDTX Analyst Recommendation Trends
In the current month, BDTX has received 5 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. BDTX average Analyst price target in the last month is 10.000.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
3
3
3
3
3
3
3
4
5
5
5
5
5
5
5
5
1
1
1
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
9
9
9
9
9
9
9
9
BDTX Analyst Rating for Peer Comparison
Updated: Sep 23, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
1
0
28
argenx SE
ARGX
10
13
3
0
0
26
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
9
12
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
6
7
1
1
20
Financial Forecasting
Based on analysts' estimates, BDTX EPS is projected to reach -0.196 in FY2026Q3, following reported EPS of -0.173 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.19
-0.18
-0.20
-0.20
-0.19
Actual
-0.26
-0.16
-0.17
--
--
Surprise
-42.20%
+14.54%
+11.66%
--
--
FAQs
What is Black Diamond Therapeutics Inc's price target?
Analysts forecast that Black Diamond Therapeutics Inc's price target is USD 10.00, with the highest forecast at USD 14.00 and the lowest forecast at USD 8.00.
How have Black Diamond Therapeutics IncBDTX's recent earnings per share performed?
The market expectation was USD -0.17, while Black Diamond Therapeutics IncBDTX's earnings per share (EPS) for the previous quarter was USD -0.16. EPS for the next quarter is expected at USD -0.20.
What is the analyst rating for Black Diamond Therapeutics Inc?
Based on the ratings of Black Diamond Therapeutics Inc's stock from 9 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.